Saudi Arabia Inflammatory Bowel Disease Treatment Market Size & Outlook
Related Markets
Saudi Arabia inflammatory bowel disease treatment market highlights
- The Saudi Arabia inflammatory bowel disease treatment market generated a revenue of USD 72.2 million in 2023 and is expected to reach USD 110.9 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, crohn's disease was the largest revenue generating type in 2023.
- Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.
Inflammatory bowel disease treatment market data book summary
| Market revenue in 2023 | USD 72.2 million |
| Market revenue in 2030 | USD 110.9 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Crohn's disease |
| Fastest growing segment | Ulcerative Colitis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Crohn's Disease, Ulcerative Colitis |
| Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.3% of the global inflammatory bowel disease treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 79.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inflammatory Bowel Disease Treatment Market Scope
Inflammatory Bowel Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | http://www.celltrionhealthcare.com/ |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Saudi Arabia inflammatory bowel disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 55.96% in 2023. Horizon Databook has segmented the Saudi Arabia inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
With low local output of branded drugs compared to generic products, Saudi Arabia has the largest pharmaceutical market in the Middle East and African region. Moreover, the country is witnessing an increased incidence of IBD.
According to Karger International, incidence of IBD in Arab countries is high. Patients with IBD from Arab countries may present different characteristics as compared to people in European countries. In addition, favorable regulatory regulations to foster IBD care in the kingdom are expected to drive the market.
For instance, in December 2022, Takeda and the Saudi Gastroenterology Association partnered to advance IBD care in the country. This partnership aimed at raising awareness about IBD and advance capabilities & knowledge across Saudi’s healthcare sector.
Reasons to subscribe to Saudi Arabia inflammatory bowel disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Saudi Arabia inflammatory bowel disease treatment market databook
-
Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Saudi Arabia inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)
Saudi Arabia Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
